Introduction {#S0001}
============

Cancer is one of the major public health burden with over 18.1 million new cancer cases and 9.6 million cancer deaths in 2018.[@CIT0001] According to assessments of World Health Organization in 2015, cancer is among the leading cause of death in most countries. The reasons may be very complex. Aging and growth of the population, as well as risk factors for cancer, might influence the development of cancer. Recently, accumulating evidence indicates that there is a connection between diabetes and obesity with cancer.[@CIT0002] Thus, any variation in diabetes and obesity-related genes may influence the risk of cancer.

LEP, a 16-kDa adipocyte-derived peptide hormone, is a mediator of obesity and homeostasis. LEP interacts with the LEP receptor and its function is mediated through this receptor. Previous studies have demonstrated that the LEP signal may be transmitted through several signaling pathways (eg JAK/STAT, MAPK, PI3K, Wnt/β-catenin, and ERK).[@CIT0003],[@CIT0004] It is also reported that LEP may affect angiogenesis, inflammation, thrombosis, and tumor growth, invasion, and metastasis.[@CIT0004]--[@CIT0013] Hardwick et al reported that LEP was very important for phosphorylation of the p42/44 mitogen-activated protein kinase and for enhancing proliferation of colonic epithelial cells.[@CIT0014] It is well known that single-nucleotide polymorphisms (SNPs) in genes may be implicated in the pathogenesis of a number of cancers and can be used as an indicator of early screening, diagnostics, and prevention measures.[@CIT0015] The human LEP gene maps to chromosome 7 (location: 128241278--128257629, NCBI Build 38). The *LEP* gene is polymorphic. And *LEP* SNPs may influence the risk of cancer.[@CIT0016] The rs7799039 G\>A (G2548A) polymorphism in the *LEP* gene is the most widely studied for its relationship between this locus and the risk of human diseases. Terrasi et al suggested that the occurrence of *LEP* rs7799039 G\>A variants could promote LEP protein expression in breast cancer cells through a Sp1- and nucleolin-dependent pathway, resulting in the LEP overexpression in tumor tissue.[@CIT0017]

Recently, many molecular epidemiological studies have been carried out to identify the relationship between the *LEP* rs7799039 G\>A polymorphism and cancer risk, but the findings have been conflicting. Three meta-analyses have been performed to explore the relationship between this SNP and cancer risk.[@CIT0018]--[@CIT0020] Results of these studies indicated that individuals carrying the *LEP* rs7799039 A allele might have an increased susceptibility of overall cancer. However, only a case--control study focusing on the association between the *LEP* rs7799039 G\>A polymorphism and the risk of gastric cancer was included.[@CIT0021] The relationship of this polymorphism with cancer risk in Asians is unclear. Recently, several case--control studies conducted in Asians were carried out to explore the association between the *LEP* rs7799039 G\>A polymorphism and cancer risk. To obtain a more precise assessment of the correlation of *LEP* rs7799039 G\>A polymorphism with the risk of cancer, we performed an updated meta-analysis of all eligible studies focusing on the relationship of the rs7799039 G\>A polymorphism to the susceptibility of developing cancer.

Materials and methods {#S0002}
=====================

Search strategy {#S0002-S2001}
---------------

In this meta-analysis, we carried out an electronic literature retrieval in PubMed, Embase, and the China Biology Medicine databases up to August 2018 using the following search strategies: ('LEP" or "leptin") and ("carcinoma" or "cancer" or 'malignancy ' or "neoplasms") and ("polymorphism" or "SNP" or "variation"). There was no restriction on language. The references in included studies and reviewers were carefully checked for other potential data. When a publication involved some subgroups, it was treated separately. This study was reported based on the Preferred Reporting Items for Meta-analyses (PRISMA) guideline ([[Table S1: PRISMA checklist](https://www.dovepress.com/get_supplementary_file.php?f=190093.pdf)]{.ul}).[@CIT0022]

Selection and exclusion criteria {#S0002-S2002}
--------------------------------

The major selection criteria were as follows: (1) designed as case--control study that assessed the relationship between *LEP* rs7799039 G\>A variants and cancer risk; (2) presented sufficient data (eg genotype number or other available data) to calculate the pooled-estimating; and (3) genotype distribution in controls did not violate Hardy--Weinberg equilibrium (HWE).

The exclusion criteria were defined as follows: (1) the publication was not designed as a case--control study; (2) the genotype data was not presented or could not be calculated; (3) genotype distribution in controls violated HWE; and (4) review articles and letters.

Data extraction {#S0002-S2003}
---------------

Two authors (W. Tang and C. Liu) independently extracted the information from each eligible study. If the extracted information was different, they would review the publication again and reached consensus. If they could not get a consistent assessment, another author (H. Qiu) would be invited to resolve the dispute and a final decision was made. The following data were extracted from each study: the surname of the first author, year of publication, country, ethnicity, numbers of participants, source of control, genotype frequencies, and genotyping method.

Statistical analysis {#S0002-S2004}
--------------------

The strength of the correlation of the *LEP* rs7799039 G\>A polymorphism with cancer susceptibility was determined by crude ORs with 95% CIs. The relationship between *LEP* rs7799039 G\>A and cancer risk was evaluated using allele model (A *vs* G), homozygote model (AA *vs* GG), recessive model (AA *vs* GG/GA), and dominant model (AA/GA *vs* GG). We used the Q and *I^2^* test to check the heterogeneity among the included studies. A *P*\>0.1 and *I^2^*\<50% indicated that there was low heterogeneity, and then the Mantel--Haenszel method (fixed-effects model) was used to calculate the ORs and CIs;[@CIT0023] otherwise, the DerSimonian and Laird method (random-effects model) was used to assess the association.[@CIT0024],[@CIT0025] The sources of heterogeneity were analyzed by subgroup analyses. Sensitivity analysis was analyzed by omitting an individual study in turn and re-calculating the ORs and CIs. Publication bias was checked by using Bgger's and Egger's test. An internet chi-square test was used to determine whether the distribution of the genotypes in controls conformed to HWE (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). All data were calculated and analyzed by using Stata 12.0 software (Stata Corp., College Station, TX). A *P*\<0.05 (two-sided) was considered as statistical significance.

Results {#S0003}
=======

Study characteristics {#S0003-S2001}
---------------------

Based on the selection criteria, 30 publications focusing on the association of the *LEP* rs7799039 G\>A polymorphism with cancer risk were included.[@CIT0021],[@CIT0026]--[@CIT0053] One publication contained two independent case--control studies that we treated as two investigations.[@CIT0049] The detail selecting process is shown in [Figure 1](#F0001){ref-type="fig"}. A total of 31 case--control studies involving 25,799 subjects were included in this meta-analysis. Among them, 19 were conducted in Caucasians,[@CIT0026]--[@CIT0044] eight performed in Asians,[@CIT0021],[@CIT0045]--[@CIT0050],[@CIT0054] and four were in mixed populations.[@CIT0051]--[@CIT0053] Nine were population-based,[@CIT0027],[@CIT0028],[@CIT0030],[@CIT0033],[@CIT0037],[@CIT0038],[@CIT0043],[@CIT0044],[@CIT0050] and 22 case--control were hospital-based studies.[@CIT0021],[@CIT0026],[@CIT0029],[@CIT0031],[@CIT0032],[@CIT0034]--[@CIT0036],[@CIT0039]--[@CIT0042],[@CIT0045]--[@CIT0049],[@CIT0051]--[@CIT0054] Of all the eligible studies, 11 focused on breast cancer,[@CIT0033],[@CIT0037]--[@CIT0040],[@CIT0044],[@CIT0048],[@CIT0049],[@CIT0051],[@CIT0053] four focused on colorectal cancer (CRC),[@CIT0031],[@CIT0032],[@CIT0041],[@CIT0052] three focused on prostate cancer (PC),[@CIT0026],[@CIT0030],[@CIT0034] and 13 focused on other cancers.[@CIT0021],[@CIT0027]--[@CIT0029],[@CIT0035],[@CIT0036],[@CIT0042],[@CIT0043],[@CIT0045]--[@CIT0047],[@CIT0050],[@CIT0054] Other information includingd case--control studies in the pooled analysis is summarized in [Table 1](#T0001){ref-type="table"}. The genotypes and alleles of *LEP* rs7799039 G\>A polymorphism are shown in [Table 2](#T0002){ref-type="table"}.Table 1Characteristics of the studies in meta-analysisStudyPublication yearCountryEthnicityCancer typeSample size (case/control)Source of controlGenotype methodRibeiro et al.[@CIT0026]2004PortugalCaucasiansProstate cancer150/118HBPCR-RFLPSkibola et al.[@CIT0027]2004USACaucasiansLymphoma376/805PBTaqManWillett et al.[@CIT0028]2005UKCaucasiansLymphoma593/754PBTaqManSnoussi et al.[@CIT0051]2006TunisiaMixedBreast cancer308/222HBPCR-RFLPSlattery et al.[@CIT0052]2008USAMixedColorectal cancer1565/1965HBTaqManChovanec et al.[@CIT0029]2009CzechCaucasiansEndometrial cancer66/543HBPCRMoore et al.[@CIT0030]2009FinlandCaucasiansProstate cancer1053/1053PBTaqManPechlivanis et al.[@CIT0031]2009CzechCaucasiansColorectal cancer702/752HBTaqManVasku et al.[@CIT0032]2009CzechCaucasiansColorectal cancer102/101HBPCR-sequencingCleveland et al.[@CIT0033]2010USACaucasiansBreast cancer1059/1101PBPCRKim et al.[@CIT0021]2012KoreaAsiansGastric cancer48/48HBPCR-RFLPRibeiro et al.[@CIT0034]2012PortugalCaucasiansProstate cancer449/557HBTaqManTavil et al.[@CIT0035]2012TurkeyCaucasiansLeukemia72/70HBPCR-RFLPGarcia-Robles et al.[@CIT0053]2013MexicoMixedBreast cancer130/189HBPCRUnsal et al.[@CIT0036]2014TurkeyCaucasiansLung cancer162/130HBPCR-RFLPZhang et al.[@CIT0045]2018ChinaAsiansHepatocellular carcinoma584/923HBSNPscanHussain et al.[@CIT0046]2015IndiaAsiansOral cancer306/228HBPCR-RFLPKarakus et al.[@CIT0037]2015TurkeyCaucasiansBreast cancer199/185PBPCRMahmoudi et al.[@CIT0038]2015IranCaucasiansBreast cancer45/41PBPCR-RFLPMohammadzadeh et al.[@CIT0039]2015IranCaucasiansBreast cancer100/100HBPCR-RFLPRostami et al.[@CIT0040]2015IranCaucasiansBreast cancer203/171HBPCR-RFLPMahmoudi et al.[@CIT0041]2016IranCaucasiansColorectal cancer261/339HBPCR-RFLPAmer et al.[@CIT0042]2017EgyptCaucasiansHepatocellular carcinoma150/100HBPCR-RFLPAli et al.[@CIT0043]2017PakistanCaucasiansBladder carcinoma200/200PBPCRQiu et al.[@CIT0047]2017ChinaAsiansEsophageal cancer507/1496HBSNPscanRodrigo et al.[@CIT0044]2017Sri LankaCaucasiansBreast cancer80/80PBPCRCao et al.[@CIT0054]2015ChinaAsiansLung cancer162/200HBPCR-RFLPYuan et al.[@CIT0048]2017ChinaAsiansBreast cancer703/805HBMALDI-TOF MSLiu et al.[@CIT0049]2018ChinaAsiansBreast cancer434/440HBMALDI-TOF MSLiu et al.[@CIT0049]2018ChinaAsiansBreast cancer334/331HBMALDI-TOF MSZhang et al.[@CIT0050]2014USAMixedPancreatic cancer173/476PBTaqMan[^2] Table 2Distribution of *LEP* rs7799039 G\>A polymorphism genotype and alleleStudyPublication yearCase AACase AGCase GGControl AAControl AGControl GGCase ACase GControl AControl GHWERibeiro et al.[@CIT0026]200424893012624413714986150YesSkibola et al.[@CIT0027]200491167118167376259349403710894YesWillett et al.[@CIT0028]2005127294170145348260548634638868YesSnoussi et al.[@CIT0051]2006371521191199112226390121323YesSlattery et al.[@CIT0052]20082847824993939386341350178017242206YesChovanec et al.[@CIT0029]20092033131312551497359517553YesMoore et al.[@CIT0030]20092814532132164372101015879869857YesPechlivanis et al.[@CIT0031]2009120309230150334227549769634788YesVasku et al.[@CIT0032]20092441352044368911184116YesCleveland et al.[@CIT0033]201022649234118056136094411749211281YesKim et al.[@CIT0021]2012291813314176208016YesRibeiro et al.[@CIT0034]20127321216484268203358540436674YesTavil et al.[@CIT0035]201226311527291483618357YesGarcia-Robles et al.[@CIT0053]2013227137469548115145187191YesUnsal et al.[@CIT0036]2014508626276340186138117143YesZhang et al.[@CIT0045]2014AA+AG:122-51AA+AG:318-158\-\-\--YesHussain et al.[@CIT0046]2015501541022392113254358138318YesKarakus et al.[@CIT0037]20154910545479840203195192178YesMahmoudi et al.[@CIT0038]2015271171719565255329YesMohammadzadeh et al.[@CIT0039]201536559524531277314951YesRostami et al.[@CIT0040]20151156424637731294112203139YesCao et al.[@CIT0054]2015577530338087189135146254YesMahmoudi et al.[@CIT0041]2016761355011315472287235380298YesAmer et al.[@CIT0042]20176069214947418911114555YesAli et al.[@CIT0043]201761103366110039225175222178YesQiu et al.[@CIT0047]2017291184297975911017662422185793YesRodrigo et al.[@CIT0044]201732435532431075313030YesYuan et al.[@CIT0048]2017416GG+GA:276-426GG+GA:347\-\-\-\--YesZhang et al.[@CIT0050]201829522159505360568113391370472YesLiu et al.[@CIT0049]2018252GG+GA:182-236GG+GA:206\-\-\-\--YesLiu et al.[@CIT0049]2018201GG+GA:133-190GG+GA:141\-\-\-\--Yes[^3] Figure 1Flow diagram of the meta-analysis of the association between *LEP* rs7799039 G\>A polymorphism and overall cancer risk.

Meta-analysis results {#S0003-S2002}
---------------------

[Table 3](#T0003){ref-type="table"} summarizes the results of this meta-analysis. We found that the *LEP* rs7799039 G\>A polymorphism was associated with overall cancer risk ([Figure 2)](#F0002){ref-type="fig"}. The A *vs* G genetic model has an OR = 1.10 with a 95% CI = 1.00--1.21 and a *P* = 0.051. The AA *vs* GG genetic model has an OR = 1.22 with a 95% CI = 1.01--1.48, and a *P* = 0.042. When we compared AA/GA *vs* GG model, we found an OR = 1.16 with a 95% CI = 1.02--1.33 and *P *= 0.026. Comparing the AA genotype with GA/GG, we calculated an OR =1.12 with a 95% CI = 1.00--1.26 and a *P *= 0.059.Table 3Results of the meta-analysis from different genetic modelsNo. of cases/controlsA vs GAA vs GGAA+GA vs GGAA vs.GA+GGOR (95% CI)*PI*^2^*P*(Q-test)OR (95% CI)*PI^2^P*(Q-test)OR (95% CI)*PI^2^P*(Q-test)OR (95% CI)*PI^2^P*(Q-test)Total11,276/14,5231.10(0.1.00--1.21)0.05179.1%\<0.001**1.22(1.01--1.48)0.042**74.9%\<0.001**1.16(1.02--1.33)0.026**68.3%\<0.0011.12(1.00--1.26)0.05969.6%\<0.001Ethnicity Caucasians6,022/7,2001.07(0.96--1.18)0.21669.5%\<0.0011.18(0.98--1.41)0.08858.5%0.0011.11(0.97--1.27)0.12249.2%0.0081.09(0.92--1.28)0.31467.2%\<0.001 Mixed2,176/2,8521.07(0.78--1.47)0.68783.9%0.0021.17(0.55--2.48)0.67683.9%0.0021.14(0.90--1.45)0.27956.4%0.0761.08(0.58--2.00)0.81681.0%0.005 Asians3,078/4,4711.27(0.87--1.87)0.21691.7%\<0.0011.60(0.67--3.80)0.28790.6%\<0.0011.42(0.71--2.85)0.32689.6%\<0.001**1.23(1.01--1.49)0.044**70.0%0.001Cancer type Prostate cancer1,652/1,7281.17(0.97--1.40)0.09859.5%0.0851.36(0.94--1.97)0.10656.8%0.0991.24(0.89--1.72)0.20870.7%0.033**1.24(1.04--1.47)0.014**0.0%0.470 Breast cancer3,595/3,6651.02(0.79--1.31)0.87882.4%\<0.0011.11(0.70--1.75)0.66971.3%0.0011.07(0.84--1.38)0.57646.1%0.0721.12(0.87--1.43)0.38578.3%\<0.001 Colorectal cancer2,630/3,1570.95(0.88--1.03)0.2030.0%0.6710.90(0.77--1.05)0.1690.0%0.6750.99(0.88--1.11)0.8490.0%0.615**0.88(0.77--1.00)0.046**0.0%0.699 Others3,399/5,9731.17(0.98--1.40)0.08182.7%\<0.0011.34(0.92--1.94)0.12781.1%\<0.0011.25(0.95--1.65)0.10478.2%\<0.0011.18(0.98--1.42)0.08363.0%0.002System of cancer Reproductive and breast cancer5,313/5,9361.10(0.95--1.29)0.20775.9%\<0.0011.28(0.98--1.68)0.07463.0%0.0021.15(0.97--1.37)0.10547.9%0.0321.17(0.97--1.40)0.09670.7%\<0.001 Hematopoietic malignancy1,041/1,629**1.13(1.01--1.26)0.038**0.0%0.595**1.25(1.00--1.55)0.049**0.0%0.6801.17(0.99--1.39)0.0680.0%0.3991.15(0.95--1.39)0.1400.0%0.730 Digestive system cancer4,398/6,4280.99(0.86--1.13)0.83873.4%\<0.0010.94(0.70--1.25)0.65870.4%0.0011.01(0.81--1.27)0.92871.7%\<0.0010.95(0.82--1.09)0.45447.5%0.055 Others524/5301.60(0.96--2.66)0.07088.2%\<0.0012.48(0.99--6.23)0.05385.1%0.001**2.06(1.05--4.02)0.035**80.3%0.0061.66(0.90--3.03)0.10278.6%0.009Sample size \<10003,685/4,3121.13(0.94--1.37)0.20081.6%\<0.0011.32(0.92--1.90)0.12974.8%\<0.001**1.29(1.03--1.62)0.027**64.3%\<0.0011.15(0.92--1.43)0.22473.3%\<0.001 ≥10007,591/10,2111.04(0.96--1.12)0.37862.4%0.0061.05(0.88--1.26)0.55967.9%0.0021.01(0.90--1.13)0.83651.2%0.0371.09(0.97--1.23)0.13561.6%0.005Source of control Hospital-based7,498/9,8281.13(0.98--1.30)0.08783.6%\<0.0011.26(0.94--1.68)0.11881.3%\<0.0011.21(0.98--1.49)0.07377.7%\<0.0011.13(0.98--1.31)0.10071.1%\<0.001 Population-based3,778/4,6951.08(0.97--1.19)0.15147.6%0.064**1.24(1.09--1.42)0.001**0.0%0.7311.10(0.99--1.21)0.0690.0%0.8111.11(0.90--1.37)0.31465.2%0.005 Figure 2Meta-analysis of the association between *LEP* rs7799039 G\>A polymorphism and overall cancer risk (dominant model, random-effects model).

In a subgroup analysis by ethnicity, we found an association in Asian populations with AA/GA *vs* GG having an OR = 1.23, a 95% CI = 1.01--1.49 and a *P *= 0.044, [Table 3](#T0003){ref-type="table"}.

In a subgroup analysis by cancer type, we found that the *LEP* rs7799039 G\>A polymorphism moderately increased the risk of PC; AA *vs* GA/GG: OR =1.24, 95%CI = 1.04--1.470, *P *= 0.014. However, we found that this G\>A polymorphism might actually confer a decreased the risk to CRC, AA *vs* GA/GG: OR =0.88, 95%CI = 0.77--1.00, *P *= 0.046. When we conducted a subgroup analysis by cancer system, we found that this G\>A polymorphism might increase the susceptibility of hematopoietic cancer; A *vs* G: OR = 1.13, 95% CI = 1.01--1.26, *P* = 0.038; AA *vs* GG: OR = 1.25, 95% CI = 1.00--1.55, *P* = 0.049) and other system cancers (AA/GA *vs* GG: OR = 2.06, 95% CI = 1.05--4.02, *P *= 0.035.

Heterogeneity analysis {#S0003-S2003}
----------------------

For this meta-analysis, we found that there was significant heterogeneity among the included case--control studies ([Table 3)](#T0003){ref-type="table"}. To identify the major sources of heterogeneity, we carried out subgroup analyses. The results indicated that Asians, small sample size studies (\<1000), and hospital-based studies might lead to the major heterogeneity in this meta-analysis.

Sensitivity analysis {#S0003-S2004}
--------------------

Sensitivity analysis was conducted by deleting an individual study in turn and calculating the pooled ORs and CIs of the remaining studies. For this SNP, the results under all genetic comparisons were not influenced by removing any eligible study ([Figure 4)](#F0004){ref-type="fig"}.Figure 3Begg's funnel plot of meta-analysis of the association between *LEP* rs7799039 G\>A polymorphism and cancer risk (dominant genetic model, random-effects model).

Publication bias {#S0003-S2005}
----------------

Begg's test and Egger's test were used to determine whether there was publication bias in genetic comparisons. The shapes of the Begg's funnel plot revealed that they were symmetrical; A *vs* G had a *P* ~Begg's~= 0.588, AA *vs* GG had a *P* ~Begg's~= 0.802; AA/GA *vs* GG had a *P* ~Begg's~* *= 0.953; and AA *vs* GA/GG had a *P* ~Begg's~= 0.887 ([Figure 3)](#F0003){ref-type="fig"}. The results of Egger's test also highlighted that there was no evidence of publication bias (A *vs* G: *P*~Egger's~ = 0.559; AA *vs* GG: *P*~Egger's~ = 0.579; AA/GA *vs* GG: *P*~Egger's~* *= 0.639 and AA *vs* GA/GG: *P*~Egger's~* *= 0.660).Figure 4Sensitivity analysis of the influence of dominant model (random-effects estimates).

Discussion {#S0004}
==========

The adipocyte-derived peptide hormone LEP has a well-known influence on inflammation, tumor growth, and metastasis. Rs7799039 G\>A is a common promoter SNP in the *LEP* gene, that may affect the transcriptional level and LEP expression.[@CIT0055] We therefore hypothesized that the *LEP* rs7799039 G\>A polymorphism might be closely related to the susceptibility of cancer. Although a number of studies have focused on the relationship between the *LEP* rs7799039 G\>A polymorphism and cancer risk, the observed results have been inconsistent. Three meta-analyses carried out by Liu et al[@CIT0018], He et al[@CIT0019], and Yang et al[@CIT0020], including 12, 15, and 15 eligible case--control studies, respectively, yielded conflicting results in some subgroups. Of late, some new data regarding the relationship of the *LEP* rs7799039 G\>A polymorphism and cancer risk have been reported.[@CIT0036]--[@CIT0050],[@CIT0053],[@CIT0054] Therefore, an updated meta-analysis is needed to address this issue. In our meta-analysis, data of 31 independent case--control studies including 11,276 cancer cases and 14,523 controls were pooled, which is more participants than were in the meta-analyses mentioned above. Thus, this updated analysis should be more comprehensive. To the best of our knowledge, the present study is the most convincing pooled analysis to explore the association between the *LEP* rs7799039 G\>A polymorphism and cancer risk. Results of our meta-analysis did indicate that the *LEP* rs7799039 G\>A polymorphism was associated with an increased risk of overall cancer, especially in Asians, PC, hematopoietic malignancy, and other system cancer subgroups.

With the accumulating evidence of genetic association investigations, it is urgent to synthesize all available data to obtain a robust result. According to the findings, the association of increased cancer risk with the *LEP* rs7799039 G\>A polymorphism was found in overall populations. Race also could be a critical biological factor for the genetic comparison. In previous meta-analyses,[@CIT0018]--[@CIT0020] most of the eligible studies contained only Caucasians. In the current study, more case--control studies included Asians.[@CIT0021],[@CIT0045]--[@CIT0050],[@CIT0054] The results suggest that the *LEP* rs7799039 G\>A polymorphism might increase the risk of cancer in Asians. We are the first to report the relationship between this SNP and cancer risk in this ethnicity.

An interesting phenomenon observed during stratified analysis was that the *LEP* rs7799039 G\>A polymorphism decreased the risk of CRC, while this SNP increased the risk of PC, other cancers, and hematopoietic malignancy. One possible explanation is that there were insufficient sample sizes for subgroup analysis. Although our findings were stable by one-way sensitivity analysis, publication bias was not found.

Among the included studies, significant heterogeneity was found in four genetic models for overall analysis. Stratified analyses indicated that heterogeneity was significant in some subgroups (eg Asians, small sample sizes, and hospital-based studies). These factors may contribute to the major heterogeneity in this study.

Several limitations, in this meta-analysis, should be acknowledged. First, although the Begg's funnel plot and Egger's test suggested no significant publication bias, it is possible that certain unpublished data are yet to be included. Selection bias for this study might have existed. Second, for lack of detailed information in the included studies, only crude ORs and CIs were calculated. We did not carry out the analysis adjusted for other potential risk factors (eg smoking, alcohol consumption, body mass index, and vegetable intake). Finally, heterogeneity among the eligible case--control studies was statistically significant in multiple genetic models. These findings should be considered with caution.

In conclusion, this study performed an extensive assessment based on a larger sample size than the previous pooled analysis. Our study indicates that the *LEP* rs7799039 G\>A polymorphism may contribute to the development of cancer. In order to further verify or refute our findings, large well-designed epidemiological studies are warranted. As investigations among Asian populations are limited, further well-designed epidemiological studies involving a wider spectrum of subjects to explore the potential role of this SNP in Asians are needed.
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